Scott C Brakenridge is an expert in Surgery at University of Florida (United States). Scott C Brakenridge has authored 198 publications, the most recent in 2026, and is an investigator in 8 clinical trials. SLR score: 628 (community average: 125). How the SLR is computed.

LeadR Profile

Scott C Brakenridge University of Florida United States
628 ScienceLeadR Reputation 628
Network Map

Surgery

Subspecialties: Immunology - Infectiology - Critical Care

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2010 - 2026

Source: PubMed

University of Washington

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 198

Citations

Citations: 6 820 1st author: 13 Last author: 31 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Virus reactivation in acute and long COVID-19.
PMID 42557313 — stress, physiological, multiple chronic conditions, covid-19, viruses, infections, post-acute covid-19 syndrome
Nature Top journal20263
Distinct immune trajectories after severe trauma identify a Th17-biased immunophenotype in chronic critical illness.
PMID 42343164 — cytokines, interferon-gamma, cells, hypersensitivity, neutrophils, recycling, critical illness, intensive care units, wounds and injuries, infections
J Immunol20260
Early immune events during SARS-CoV-2 infection impact memory T and B cell responses.
PMID 42249109 — cells, sars-cov-2, covid-19, immunity, severe acute respiratory syndrome-related coronavirus, memory, b-lymphocytes, infections
Commun Biol20260
Generation of Interactive Knowledge Graphs to Enable Research of the Effects of Trauma Center Organization on Patient Outcomes.
PMID 42164826 — trauma centers, research, wounds and injuries
Knowl Graphs Semantic Web (2025)20250
Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19.
PMID 41840216 — genes, covid-19, azithromycin, gene expression
Nat Microbiol20260

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 4
Phase 1 2
Phase 2 1
Phase 3 1

By status:

Completed 4
Terminated 3
Active not recruiting 1

By type:

Interventional 6
Observational 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 5

Main Topics

Cohort/Consortium Investigators 12

LeadR Networks

Main global connection map